Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLC590 for Postsurgical Pain Following Inguinal Hernia Repair
NCT03591146Phase 2Completed
- Sponsor
- Taiwan Liposome Company
- Start
- Jul 2018
- Primary completion
- Jan 2019
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TLC590 in Persistent postsurgical pain (PPSP) (5 arms), sponsored by Taiwan Liposome Company. Primary endpoint: Safety and Tolerability. Started Jul 2018; status: completed.
02
Drugs
TLC590
03
Conditions
Persistent postsurgical pain (PPSP)
Beyond the preview
Go deeper on NCT03591146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03591146.